Recombinant IL-33 antibody

Catalog No. ABIN1169167

Product Details anti-IL-33 Antibody

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Antibody Type: Recombinant Antibody

Reactivity: Mouse

Host: Human

Clonality: Monoclonal

Conjugate: This IL-33 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Specificity: Recognizes mouse IL-33.

Cross-Reactivity: Mouse (Murine)

Purification: Purified from HEK 293 cell culture supernatant.

Purity: >95 % (SDS-PAGE)

Immunogen: Mouse recombinant IL-33.

Clone: Carly-1-4

Isotype: IgG2

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

anti-IL-33 (mouse), monoclonal antibody (recombinant) (Carly-1-4) is composed of human variable regions (VH and VL) (lambda-chain) of immunoglobulin fused to the human lgG2 Fc domain.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: In PBS containing 10 % glycerol and 0.02 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C.

Expiry Date: 12 months

Target Details for IL-33

Target: IL-33 (IL33) (Interleukin 33 (IL33))

Alternative Name: IL-33 (IL33 Products)

Synonyms: IL33 antibody, C9orf26 antibody, DVS27 antibody, IL1F11 antibody, NF-HEV antibody, NFEHEV antibody, RP11-575C20.2 antibody, 9230117N10Rik antibody, Il-33 antibody, Il1f11 antibody, RGD1311155 antibody, interleukin 33 antibody, IL33 antibody, Il33 antibody

Background: Interleukin-33 (IL-33, HF-NEV, IL-1F11), a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released upon cell lysis. IL-33 binds to and signals through ST2 (IL-1R1) and its stimulation recruits MYD88, IRAK, IRAK4 and TRAF6, followed by phosphorylation of ERK1 (MAPK3)/ERK2 (MAPK1), p38 (MAPK14) and JNK. The ability of IL-33 to target numerous immune cell types, like Th2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of a wide range of diseases, such as arthritis, asthma, atopic allergy & anaphylaxis, cardiovascular disease/atherosclerosis, nervous system diseases and sepsis. Anti-IL-33, mAb (recombinant) (Carly-1-4) is an antibody developed by antibody phage display technology using a human naive antibody gene library. These libraries consist of scFv (single chain fragment variable) composed of VH (variable domain of the human immunoglobulin heavy chain) and VL (variable domain of the human immunoglobulin light chain) connected by a polypeptide linker. The antibody fragments are displayed on the surface of filamentous bacteriophage (M13). This scFv was selected by affinity selection on antigen in a process termed panning. Multiple rounds of panning are performed to enrich for antigen-specific scFv-phage. Monoclonal antibodies are subsequently identified by screening after each round of selection. The selected monoclonal scFv is cloned into an appropriate vector containing a Fc portion of interest and then produced in mammalian cells to generate an IgG like scFv-Fc fusion protein.

UniProt: Q8BVZ5

Pathways: Production of Molecular Mediator of Immune Response